JP2011173853A - 2,4-diaminopyrimidine compound having substituted aminoadamantylalkyl group - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a compound useful as an active ingredient for medicines having PKCθ-inhibiting activity, especially for medicine compositions for inhibiting acute rejections in transplantation. <P>SOLUTION: A compound having a PKCθ-inhibiting activity has been examined. It has consequently been confirmed that a compound characterized by having a structure such as an aralkyl group on the 2-positioned amino group of 2,4-diaminopyrimidine and further having a substituted aminoadamantylalkyl group on the 4-positioned amino group or salt thereof has an excellent PKCθ-inhibiting activity, and the invention has been completed. The 2,4-diaminopyrimidine compound having a substituted aminoadamantylalkyl group can be used as a PKCθ-inhibitor, and an acute rejection inhibitor in transplantation. <P>COPYRIGHT: (C)2011,JPO&INPIT

Description

  The present invention relates to a 2,4-diaminopyrimidine compound having a substituted aminoadamantylalkyl group useful as an active ingredient of a pharmaceutical composition, particularly a pharmaceutical composition for suppressing acute rejection in transplantation.

  Protein kinase C (PKC) is one of the protein kinase families, and at least 10 types of isozyme have been identified so far, and is classified into three subfamilies based on differences in primary structure.

  The activation mechanisms of these three subfamilies are very different between subfamilies. PKC activated by calcium and diacylglycerol (DAG) is classical PKC (cPKC), activated by DAG, but PKC that does not require calcium in its activation is novel PKC (nPKC), active Types of PKC that do not require both calcium and DAG for conversion are called atypical PKC (aPKC).

Further, each subfamily consists of a plurality of isozymes, and cPKC is classified as PKCα, PKCβ, PKCγ, nPKC is classified as PKCδ, PKCε, PKCη, PKCθ, and aPKC is classified as PKCζ and PKCλ.
Although the expression distribution of each isozyme is relatively wide, the expression of PKCθ, one of nPKCs, is restricted to T lymphocytes and skeletal muscle. In addition, the phenotype of PKCθ knockout mice is inhibition of T cell signaling and induction of T cell anergy, and no abnormalities in skeletal muscle have been detected. Therefore, PKCθ is a target for immunosuppressants with few side effects. Promising.

  In addition, in the T cell receptor signal transduction pathway, calcineurin, which is a target molecule of FK506 and cyclosporin A widely used in current transplantation medicine, and PKCθ have a complementary relationship, so calcineurin inhibitor and PKCθ There is a possibility that a synergistic immunosuppressive effect is exhibited by the combined use of inhibitors.

Therefore, by selectively inhibiting PKCθ, immunosuppressive activity is expressed with few side effects, and in transplantation medicine, there is a possibility that synergistic immunosuppressive activity can be expressed when used in combination with a calcineurin inhibitor. It is thought that there is.

（式中のR2は

等を表す。その他の記号は当該公報参照。） In Patent Document 1, it is reported that the compound represented by the formula (A) inhibits PKCθ and is useful as an immunosuppressant. Although a compound having a pyrimidine structure is disclosed as a specific compound, there is no specific disclosure of the compound of the present invention.

(R2 in the formula is

Etc. For other symbols, see the publication. )

（式中のR3は

を表す。その他の記号は当該公報参照。） Patent Document 2 reports that the compound represented by the formula (B) inhibits PKCθ and is useful as an immunosuppressant. Although a compound having a pyrimidine structure is disclosed as a specific compound, there is no specific disclosure of the compound of the present invention.

(R3 in the formula is

Represents. For other symbols, see the publication. )

（式中のR1は

を表す。その他の記号は当該公報参照。） In Patent Document 3, it is reported that the compound represented by the formula (C) inhibits PKCθ and is useful as an immunosuppressant. Although a compound having a pyrimidine structure is disclosed as a specific compound, there is no specific disclosure of the compound of the present invention.

(R1 in the formula is

Represents. For other symbols, see the publication. )

（式中の記号は当該公報参照。） In Patent Document 4, the compound represented by the formula (D) has an inhibitory activity against cyclin-dependent kinase (CDK), Aurora B kinase, etc., and is used for treatment and prevention of diseases characterized by excessive or abnormal cell proliferation. It has been reported to be useful. Although a compound having a pyrimidine structure is disclosed as a specific compound and is described as being useful for immunosuppression in organ transplantation, there is no specific disclosure of the compound of the present invention.

(See the official gazette for symbols in the formula.)

（式中の記号は当該公報参照。） In Patent Document 5, the compound represented by the formula (E) inhibits polo-like kinase (PLK) and is useful for prevention and / or treatment of tumors, neurodegenerative diseases, and diseases related to immune system activation. It has been reported. Although a compound having a pyrimidine structure is disclosed as a specific compound, there is no specific disclosure of the compound of the present invention, and no effect on PKCθ inhibitory activity or acute rejection in transplantation is disclosed at all.

(See the official gazette for symbols in the formula.)

（式中のR1は水素等、Aは置換されていてもよい複素環基、置換されていてもよい複素環アルキル、置換されていてもよいC_3-8シクロアルキル等を表す。その他の記号は当該公報参照。） Patent Document 6 reports that the compound represented by the formula (F) inhibits G protein-coupled receptor protein 88 (GPR88) and is useful for the prevention and / or treatment of central diseases. Although a compound having a pyrimidine structure is disclosed as a specific compound, there is no specific disclosure of the compound of the present invention, and no effect on PKCθ inhibitory activity or acute rejection in transplantation is disclosed at all.

(Wherein R1 represents hydrogen, A represents an optionally substituted heterocyclic group, an optionally substituted heterocyclic alkyl, an optionally substituted C _3-8 cycloalkyl, etc.) (See the publication.)

International Publication No. 2004/067516 Pamphlet International Publication No. 2006/014482 Pamphlet International Publication No. 2007/076247 Pamphlet International Publication No. 2003/032997 Pamphlet International Publication No. 2004/043936 Pamphlet International Publication No. 2004/054617 Pamphlet

  An object of the present invention is to provide a 2,4-diaminopyrimidine compound having a substituted aminoadamantylalkyl group useful as an active ingredient of a pharmaceutical having PKCθ inhibitory activity, particularly a pharmaceutical composition for suppressing acute rejection in transplantation.

（式中、
R¹は、

を示し；
R²は、-CN、-NO₂又はハロゲンを示し；
nは、1又は2を示し；
R³は、同一又は互いに異なって、ハロゲン、-OH、-CN、置換されていてもよいC_1-6アルキル、シクロアルキル、-Q-(置換されていてもよいC_1-6アルキル)又は-Q-シクロアルキルを示し；
Qは、O、S、SO又はSO₂を示し；及び
Aは、CH又はNを示す。）
なお、特に記載がない限り、本明細書中のある化学式中の記号が他の化学式においても用いられる場合、同一の記号は同一の意味を示す。 As a result of studying compounds having PKCθ inhibitory activity, the present inventors have a structure such as aralkyl on the 2-position amino group of 2,4-diaminopyrimidine, and further a substituted aminoadamantylalkyl group on the 4-position amino group. The present invention was completed by discovering that a compound or a salt thereof characterized by having excellent PKCθ inhibitory activity.
That is, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, as well as a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable salt. The present invention relates to a pharmaceutical composition containing a form.

(Where
R ¹ is

Indicates;
R ² represents —CN, —NO ₂ or halogen;
n represents 1 or 2;
R ³ is the same or different from each other, and is halogen, —OH, —CN, optionally substituted C _1-6 alkyl, cycloalkyl, —Q— (optionally substituted C _1-6 alkyl) or Represents -Q-cycloalkyl;
Q represents O, S, SO or SO ₂ ; and
A represents CH or N. )
Unless otherwise specified, when a symbol in a chemical formula in this specification is also used in another chemical formula, the same symbol indicates the same meaning.

The present invention also relates to a PKCθ inhibitor containing a compound of formula (I) or a pharmaceutically acceptable salt thereof, and an acute rejection inhibitor for transplantation.
Furthermore, the present invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of an acute rejection inhibitor in transplantation, as well as a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present invention relates to a method for suppressing acute rejection in transplantation, which comprises administering to a patient an effective amount of an acceptable salt.

  The compound of the formula (I) or a pharmaceutically acceptable salt thereof has a PKCθ inhibitory action and can be used as an inhibitor of acute rejection in transplantation.

Hereinafter, the present invention will be described in detail.
In the present specification, “C _1-6 alkyl” means a linear or branched alkyl having 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec -Butyl, tert-butyl, n-pentyl, n-hexyl group, and the like. In another embodiment, C _1-4 alkyl is used. In another embodiment, methyl and ethyl are used.

In the present specification, “cycloalkyl” is a C _3-10 saturated hydrocarbon ring group, which may have a bridge. For example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl and the like. Another embodiment is C _3-8 cycloalkyl, yet another embodiment is C _3-6 cycloalkyl, and yet another embodiment is cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

  In the present specification, “halogen” means F, Cl, Br and I.

In the present specification, “optionally substituted” in “optionally substituted C _1-6 alkyl” means that the C _1-6 alkyl moiety is unsubstituted or halogen, —CN, —OH. And 1 to 5 substituents selected from the group consisting of cycloalkyl and, as another aspect, unsubstituted or substituted with 1 to 5 halogens or —OH In still another embodiment, it is unsubstituted or substituted with 1 to 3 —F or —OH. In addition, when it has a some substituent, those substituents may be the same or may mutually differ.

Certain embodiments of the compound of formula (I) are shown below.
(1) The compound wherein R ² is —CN, —NO ₂ or —F, and in another embodiment, is —CN.
(2) A compound wherein n is 1.
(3) R ³ may be substituted with halogen, —OH, —CN, —OH, C _1-6 alkyl, cycloalkyl, —Q— (optionally substituted with halogen or —OH C _{1 -6} alkyl) or -Q-cycloalkyl, and in another embodiment, C _1-6 alkyl, cycloalkyl, -O- (halogen optionally substituted with halogen, -OH, -CN, -OH Or C _1-6 alkyl optionally substituted with -OH), -S- (C _1-6 alkyl), -SO- (C _1-6 alkyl), -SO _2- (C _1-6 alkyl) Or -S-cycloalkyl, and in still another embodiment, -Cl, -O-CH ₃ , -O-CHF ₂ , -O-CF ₃ , -O-CH ₂ CF ₃ or -S-CH ₃ A compound that is
(4) A compound in which A is CH, and in another embodiment, A is N.
(5) A compound which is a combination of two or more of the embodiments described in (1) to (4) above.
(6) A compound selected from the following group.
rel-4-({[(1S, 3R, 4S, 5S) -4-{[(4-hydroxybicyclo [2.2.2] oct-1-yl) methyl] amino} adamantan-1-yl] methyl} amino ) -2-{[2- (trifluoromethoxy) benzyl] amino} pyrimidine-5-carbonitrile,
rel-2-[(2-chlorobenzyl) amino] -4-({[(1S, 3R, 4S, 5S) -4-{[(4-hydroxybicyclo [2.2.2] oct-1-yl) methyl ] Amino} adamantan-1-yl] methyl} amino) pyrimidine-5-carbonitrile,
rel-2-{[2- (difluoromethoxy) benzyl] amino} -4-({[(1S, 3R, 4S, 5S) -4-{[(4-hydroxybicyclo [2.2.2] oct-1- Yl) methyl] amino} adamantan-1-yl] methyl} amino) pyrimidine-5-carbonitrile,
rel-4-({[(1S, 3R, 4S, 5S) -4-{[(4-hydroxybicyclo [2.2.2] oct-1-yl) methyl] amino} adamantan-1-yl] methyl} amino ) -2-{[2- (2,2,2-trifluoroethoxy) benzyl] amino} pyrimidine-5-carbonitrile,
rel-4-({[(1S, 3R, 4S, 5S) -4-{[(4-hydroxybicyclo [2.2.2] oct-1-yl) methyl] amino} adamantan-1-yl] methyl} amino ) -2-({[2- (methylsulfanyl) pyridin-3-yl] methyl} amino) pyrimidine-5-carbonitrile, and
rel-4-({[(1S, 3R, 4S, 5S) -4-{[(4-hydroxybicyclo [2.2.2] oct-1-yl) methyl] amino} adamantan-1-yl] methyl} amino ) -2-{[(2-Methoxypyridin-3-yl) methyl] amino} pyrimidine-5-carbonitrile.

In the compound of the formula (I), tautomers and geometric isomers may exist depending on the type of substituent. In the present specification, the compound of the formula (I) may be described in only one form of an isomer, but the present invention includes other isomers, separated isomers, or those isomers. And mixtures thereof.
In addition, the compound of formula (I) may have an asymmetric carbon atom or axial asymmetry, and optical isomers based on this may exist. The present invention also includes separated optical isomers of the compound of formula (I) or a mixture thereof.

  Furthermore, this invention also includes the pharmaceutically acceptable prodrug of the compound shown by a formula (I). Pharmaceutically acceptable prodrugs are compounds that are converted to the compounds of the present invention by solvolysis or under physiological conditions. Examples of groups that form prodrugs include those described in Prog. Med., 5, 2157-2161 (1985) and “Development of Pharmaceuticals” (Yodogawa Shoten, 1990), Volume 7, Molecular Design 163-198. Is mentioned.

  The salt of the compound of the formula (I) is a pharmaceutically acceptable salt of the compound of the formula (I), and may form an acid addition salt or a salt with a base depending on the type of substituent. is there. Specifically, inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid Acid addition with organic acids such as lactic acid, malic acid, mandelic acid, tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, aspartic acid, glutamic acid Salts, salts with inorganic bases such as sodium, potassium, magnesium, calcium, and aluminum, organic bases such as methylamine, ethylamine, ethanolamine, lysine, ornithine, salts with various amino acids and amino acid derivatives such as acetylleucine, and ammonium Examples include salts.

  Furthermore, the present invention also includes various hydrates and solvates of the compound of the formula (I) and pharmaceutically acceptable salts thereof, and crystalline polymorphic substances. The present invention also includes compounds labeled with various radioactive or non-radioactive isotopes.

(Production method)
The compound of the formula (I) and pharmaceutically acceptable salts thereof can be produced by applying various known synthetic methods utilizing characteristics based on the basic structure or the type of substituent. At that time, depending on the type of functional group, it is effective in terms of production technology to replace the functional group with an appropriate protective group (a group that can be easily converted into the functional group) at the stage from the raw material to the intermediate. There is a case. Examples of such protecting groups include protecting groups described in “Greene's Protective Groups in Organic Synthesis (4th edition, 2006)” by PGM Wuts and TW Greene. These may be appropriately selected according to the reaction conditions. In such a method, after carrying out the reaction by introducing the protective group, the desired compound can be obtained by removing the protective group as necessary.
In addition, the prodrug of the compound of formula (I) introduces a specific group at the stage from the raw material to the intermediate as in the case of the protective group, or further reacts with the obtained compound of formula (I). Can be manufactured. The reaction can be carried out by applying methods known to those skilled in the art, such as ordinary esterification, amidation, dehydration and the like.
Hereinafter, typical production methods of the compound of the formula (I) will be described. Each manufacturing method can also be performed with reference to the reference attached to the said description. In addition, the manufacturing method of this invention compound is not limited to the example shown below.

本製法は、化合物（１）にR¹基のケトン体またはアルデヒド体を反応させて還元的にアルキル化し、式（Ｉ）の化合物を製造する方法である。
この反応では、化合物（１）とR¹基のケトン体またはアルデヒド体を還元剤の存在下、反応に不活性な溶媒中、-45℃〜加熱還流下、好ましくは0℃〜室温において、通常0.1時間〜5日間撹拌する。ここで用いられる溶媒の例としては、特に限定されないが、メタノール、エタノール等のアルコール類、ジクロロメタン、1,2-ジクロロエタン若しくはクロロホルム等のハロゲン化炭化水素類、ジエチルエーテル、テトラヒドロフラン、ジオキサン、ジメトキシエタン等のエーテル類、N,N-ジメチルホルムアミド及びこれらの混合物が挙げられる。還元剤としては、シアン化水素化ホウ素ナトリウム、トリアセトキシ水素化ホウ素ナトリウム、水素化ホウ素ナトリウム等が挙げられる。モレキュラーシーブス等の脱水剤、又は酢酸、塩酸、チタニウム（IV）イソプロポキシド錯体等の酸存在下で反応を行うことが好ましい場合がある。反応によっては、カルボニル化合物と一級又は二級アミン化合物との縮合によりイミンが生成し、安定な中間体として単離できる場合がある。そのような場合には、イミン中間体を単離した後に、還元反応により目的物を得ることもできる。また、前記還元剤での処理の代わりに、メタノール、エタノール、酢酸エチル等の溶媒中、酢酸、塩酸等の酸の存在下又は非存在下で、還元触媒（例えば、パラジウム炭素、ラネーニッケル等）を用いて反応を行うこともできる。この場合、反応を常圧から50気圧の水素雰囲気下で、冷却下から加熱下で行うことが好ましい。
〔文献〕
A. R. Katritzky及びR. J. K. Taylor著、「Comprehensive Organic Functional Group Transformations II」、第2巻、Elsevier Pergamon、2005年
日本化学会編「実験化学講座(第5版)」14巻(2005年)(丸善) Manufacturing method 1

This production method is a method for producing a compound of formula (I) by reacting compound (1) with a ketone body or aldehyde body of R ¹ group and reductively alkylating the compound.
In this reaction, compound (1) and a ketone or aldehyde form of R ¹ group are usually present in a solvent inert to the reaction in the presence of a reducing agent at −45 ° C. to heating under reflux, preferably at 0 ° C. to room temperature. Stir for 0.1 hour to 5 days. Examples of the solvent used here are not particularly limited, but alcohols such as methanol and ethanol, halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane and chloroform, diethyl ether, tetrahydrofuran, dioxane, dimethoxyethane and the like. Ethers, N, N-dimethylformamide and mixtures thereof. Examples of the reducing agent include sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride and the like. It may be preferable to carry out the reaction in the presence of a dehydrating agent such as molecular sieves or an acid such as acetic acid, hydrochloric acid, titanium (IV) isopropoxide complex. Depending on the reaction, an imine may be generated by condensation between a carbonyl compound and a primary or secondary amine compound, and may be isolated as a stable intermediate. In such a case, the target product can also be obtained by a reduction reaction after isolating the imine intermediate. Further, instead of the treatment with the reducing agent, a reduction catalyst (for example, palladium carbon, Raney nickel, etc.) is used in a solvent such as methanol, ethanol, ethyl acetate, in the presence or absence of an acid such as acetic acid or hydrochloric acid. Can also be used to carry out the reaction. In this case, it is preferable to carry out the reaction under a hydrogen atmosphere at normal pressure to 50 atm and under cooling to heating.
[Reference]
AR Katritzky and RJK Taylor, `` Comprehensive Organic Functional Group Transformations II '', Volume 2, Elsevier Pergamon, 2005 Chemical Society of Japan, `` Experimental Chemistry Course (5th Edition) '', Volume 14 (2005) (Maruzen)

(Production method of raw material compounds)
The raw material used for the production of the compound of the present invention, that is, the amine compound (1) can be obtained by applying, for example, the method described in the following production examples, a method obvious to those skilled in the art, or a modified method thereof. It can manufacture from such a well-known compound.

The compound of formula (I) is isolated and purified as a free compound, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a crystalline polymorphic substance. The pharmaceutically acceptable salt of the compound of formula (I) can also be produced by subjecting it to a conventional salt formation reaction.
Isolation and purification are performed by applying ordinary chemical operations such as extraction, fractional crystallization, and various fractional chromatography.
Various isomers can be produced by selecting an appropriate raw material compound, or can be separated by utilizing a difference in physicochemical properties between isomers. For example, optical isomers can be obtained by general optical resolution of racemates (for example, fractional crystallization leading to diastereomeric salts with optically active bases or acids, chromatography using chiral columns, etc.). Further, it can also be produced from a suitable optically active raw material compound.

  The pharmacological activity of the compound of formula (I) was confirmed by the following test.

Test method 1: Measurement of human PKCθ enzyme inhibitory activity
Testing was performed using the HTRF ^R KinEASE ^™ S1 kit (CIS bio). Place 4 μL of the drug solution in a 384-well plate (CORNING), 3 μL of STK Substrate 1-biotin (final 250 nM) and Full-length human PKCθ (Carna Biosciences, final 31 ng / mL) mixture, and let stand at room temperature for 30 minutes, then ATP solution 3 μL (final 30 μM) was dispensed, and the enzyme reaction was performed at room temperature for 1 hour. Thereafter, 10 μL of a reaction stop solution containing Sa-XL665 (final 31.25 nM) and antibody STK-Antibody-Cryptate (final 800-fold dilution) was dispensed and left at room temperature for 1 hour. The fluorescence intensity at 620 nm (Cryptate) and 665 nm (XL665) was measured by Discovery (PACKARD), and the inhibition rate and IC ₅₀ value were calculated with the vehicle at 0% and the blank at 100%.
The test results are shown in Table 1. Ex represents an example compound number described later.

Test method 2: Measurement of human IL-2 production inhibitory activity
i) Preparation of plasmid A DNA fragment (445 bp) of the Human IL-2 promoter region corresponding to the DNA nucleotide sequence described in the database was cloned, inserted into pGL3 basic, a vector for reporter gene assay, and pGL3-IL2-pro-43 was inserted. I got it.
ii) Maintenance and passage of Jurkat cells Jurkat, Clone E6-1 (ATCC No. TIB-152), a human T cell line cultured cell, was used as a medium with 10% FBS RPMI 1640 (Sigma) at 37 ° C, 5% CO _2. Cultured under saturated humidity conditions, and subcultured when it was about 90% confluent.
iii) Transfection and seeding After measuring the number of cells using a hemocytometer, prepare a cell suspension using 10% FBS RPMI 1640 (Sigma) so that the cell concentration is 2.5 x 10 ⁷ cells / mL. Then, 10 μg of pGL3-IL2-pro-43 was mixed. Next, 400 μL of Jurkat cells adjusted to 2.5 × 10 ⁷ cells / mL were added to each prepared plasmid mixture and mixed, and the whole amount was added to Gene Pulsor ^R Cuvette (BIO-RAD). Introduce the plasmid at 300V, 975μF with Gene Pulsor ^R II (BIO-RAD), suspend the entire amount of Jurkat cells with the introduced plasmid in 2.5mL of 10% FBS RPMI 1640, and then in 96 well plate (Corning Coster) The cells were seeded at 50 μL / well and cultured under conditions of 37 ° C., 5% CO ₂ and saturated humidity for about 10 hours.
iv) Measurement of human IL-2 production inhibitory activity Add 25 μL / well of drug solution, and then add anti-CD3 antibody and anti-CD28 antibody (Pharmingen) (both 1000 μl of final concentration of 1 μg / mL) with 10% FBS RPMI1640. A mixed solution diluted 250-fold was added at a rate of 25 μL / well. This was cultured for about 14 hours under conditions of 37 ° C., 5% CO ₂ and saturated humidity. The assay was performed in duplicate.
The substrate solution attached to the Bright-Glo ^™ Luciferase Assay System (Promega) was added in an amount of 100 μL / well and gently mixed. The multi-label counter (ARVO SX, WALLAC) was set to reaction temperature: 25 ° C., Shaking Duration: 1 sec, Measurement time: 1 sec, and the measurement wells of each 96 wells plate were set to measure Firefly luciferase activity.

Test method 3: measurement of cytochrome P450 (CYP3A4) enzyme inhibitory activity
i) Inhibition test I (calculation of residual rate I)
Using a 96-well plate, substrate 2 μM (midazolam), test compound 5 μM and human liver microsome (0.1 mg protein / mL) in 100 mM phosphate buffer (pH 7.4) containing 0.1 mM EDTA, 1 mM NADPH, total volume 150 μL And incubated at 37 ° C for 20 minutes. Thereafter, 130 μL of an aqueous solution containing 80% acetonitrile was added to stop the reaction. Thereafter, the sample was analyzed by LC / MS / MS, and the residual ratio I was calculated using Equation 1 below.
(Formula 1)
Residual rate I (%) = Ai, I / Ao, I x 100
Ai, I = Metabolite production after reaction in the presence of test compound in inhibition test I
Ao, I = Amount of metabolite produced after reaction in the absence of test compound in inhibition test I
ii) Inhibition test II (calculation of residual rate II)
Using a 96-well plate, test compound 5 μM and human liver microsome (0.1 mg protein / mL) in 0.1 mM EDTA, 1 mM NADPH in 100 mM phosphate buffer (pH 7.4) total volume 145 μL at 37 ° C. for 30 minutes Incubated. Thereafter, 2 μM of the substrate midazolam was added to make a total volume of 150 μL, followed by incubation at 37 ° C. for 20 minutes. After the incubation, the reaction was stopped by adding an aqueous solution containing 80% acetonitrile, and the sample was analyzed by LC / MS / MS.
(Formula 2)
Residual rate II (%) = Ai, II / Ao, II / (Ai, I / Ao, I) x 100
Ai, II = Metabolite production after reaction in the presence of test compound in inhibition test II
Table 2 shows the test results of metabolite production after reaction in the absence of the test compound in Ao, II = inhibition test II. Ex represents an example compound number described later.

  This test confirmed that the compound of formula (I) does not significantly reduce the enzyme activity of cytochrome P450 (CYP3A4).

  As a result of each of the above tests, the compound of formula (I) has a PKCθ inhibitory action and has reduced CYP inhibition, so it is clear that it is useful as an inhibitor of acute rejection in transplantation and the like. .

A pharmaceutical composition containing one or more of the compounds of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient is a pharmaceutical excipient or drug that is usually used in the art. It can be prepared by a commonly used method using a carrier or the like.
Administration is orally by tablets, pills, capsules, granules, powders, solutions, etc., or injections such as intra-articular, intravenous, intramuscular, suppositories, eye drops, ophthalmic ointments, transdermal solutions, Any form of parenteral administration such as an ointment, a transdermal patch, a transmucosal liquid, a transmucosal patch, and an inhalant may be used.

As a solid composition for oral administration, tablets, powders, granules and the like are used. In such solid compositions, one or more active ingredients are combined with at least one inert excipient such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone. And / or mixed with magnesium aluminate metasilicate. The composition may contain an inert additive, for example, a lubricant such as magnesium stearate, a disintegrant such as sodium carboxymethyl starch, a stabilizer, or a solubilizing agent according to a conventional method. . If necessary, tablets or pills may be coated with a sugar coating or a film of a gastric or enteric substance.
Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or elixirs and the like, and commonly used inert diluents such as purified water. Or it contains ethanol. In addition to the inert diluent, the liquid composition may contain solubilizers, wetting agents, auxiliaries such as suspending agents, sweeteners, flavors, fragrances, and preservatives.

  Injections for parenteral administration contain sterile aqueous or non-aqueous solutions, suspensions or emulsions. Examples of the aqueous solvent include distilled water for injection or physiological saline. Examples of non-aqueous solvents include propylene glycol, polyethylene glycol or vegetable oil such as olive oil, alcohols such as ethanol, or polysorbate 80 (a pharmacopeia name). Such compositions may further contain isotonic agents, preservatives, wetting agents, emulsifiers, dispersants, stabilizers, or solubilizing agents. These are sterilized by, for example, filtration through a bacteria-retaining filter, blending with a bactericide or irradiation. These can also be used by producing a sterile solid composition and dissolving or suspending it in sterile water or a sterile solvent for injection before use.

  External preparations include ointments, plasters, creams, jellies, poultices, sprays, lotions, eye drops, eye ointments and the like. Contains commonly used ointment bases, lotion bases, aqueous or non-aqueous solutions, suspensions, emulsions, and the like. For example, ointment or lotion bases include polyethylene glycol, propylene glycol, white petrolatum, white beeswax, polyoxyethylene hydrogenated castor oil, glyceryl monostearate, stearyl alcohol, cetyl alcohol, lauromacrogol, sorbitan sesquioleate, etc. Can be mentioned.

  Transmucosal agents such as inhalants and nasal agents are used in solid, liquid or semi-solid form and can be produced according to conventionally known methods. For example, known excipients, and further pH adjusters, preservatives, surfactants, lubricants, stabilizers, thickeners and the like may be appropriately added. For administration, an appropriate device for inhalation or insufflation can be used. For example, using a known device such as a metered dose inhalation device or a nebulizer, the compound is administered alone or as a powder in a formulated mixture or as a solution or suspension in combination with a pharmaceutically acceptable carrier. be able to. The dry powder inhaler or the like may be for single or multiple administration, and a dry powder or a powder-containing capsule can be used. Alternatively, it may be in the form of a pressurized aerosol spray using a suitable propellant, for example, a suitable gas such as chlorofluoroalkane, hydrofluoroalkane or carbon dioxide.

  Usually, in the case of oral administration, the daily dose is about 0.0001 to 100 mg / kg per body weight, which is administered once or divided into 2 to 4 times. In the case of intravenous administration, the daily dose is appropriately about 0.0001 to 10 mg / kg per body weight, and is administered once a day or divided into multiple times. In the case of inhalation, about 0.0001 to 1 mg / kg per body weight is administered once to several times a day. The dose is appropriately determined according to individual cases in consideration of symptoms, age, sex, and the like.

  The compound of the formula (I) can be used in combination with various therapeutic agents or preventive agents for diseases for which the compound of the formula (I) is considered to be effective. The combination may be administered simultaneously, separately separately, or at desired time intervals. The simultaneous administration preparation may be a compounding agent or may be separately formulated.

  Hereinafter, based on an Example, the manufacturing method of the compound of a formula (I) is demonstrated in detail. In addition, this invention is not limited to the compound as described in the following Example. Moreover, the manufacturing method of a raw material compound is shown to a manufacture example. Further, the production method of the compound of the formula (I) is not limited to the production methods of the specific examples shown below, and the compound of the formula (I) may be a combination of these production methods or a person skilled in the art. It can also be produced by methods that are self-evident.

Moreover, the following abbreviations may be used in Examples, Production Examples, and Tables below.
PEx: Production Example Number, Ex: Example Number, Str: Structural Formula (In the structural formula, for example, when HCl is described, this means that the compound is hydrochloride, and when 2HCl is described. , Means that the compound is dihydrochloride.), Rel: Relative configuration (when there is a description of rel under the number of PEx or Ex, of the adamantane skeleton part in the structural formula described in the column of Str This means that the three-dimensional notation represents relative arrangement.), Syn: Production method (in the case of numbers only, the production number of the example produced in the same manner, and in the case where P precedes the number, the production example produced in the same manner) The numbers are shown respectively.), Dat: physicochemical data, NMR1: δ (ppm) in 1H NMR in DMSO-d ₆ , NMR2: δ (ppm) in 1H NMR in CDCl ₃ , NMR3: in D ₂ O Δ (ppm) in 1H NMR, ESI +: ESI-MS (cation), TEA: triethylamine, TFA: trifluoroacetic acid, THF: tetrahydride Furan, DMF: N, N-dimethylformamide, DME: dimethoxyethane, DMI: 1,3-dimethyl-2-imidazolidinone, MeOH: methanol, EtOAc: ethyl acetate, MeCN: acetonitrile, HOBt: 1-hydroxybenzotriazole , DIPEA: diisopropylethylamine, MCPBA: m-chloroperbenzoic acid, Pd / C: palladium on carbon.

Production Example 1
rel- (1R, 3S, 5R, 7S) -4-oxoadamantane-1-carboxylic acid (1.0 g) was dissolved in 8M ammonia in MeOH (20 ml) and 10% Pd / C (50% water content, 100 mg) ) And stirred at 25 ° C. for 10 hours under a hydrogen atmosphere of 3 atm. The precipitated product was dissolved in water (20 ml), and the catalyst was filtered off through celite. MeCN (30 ml) was added dropwise to the residue obtained by evaporating MeOH under reduced pressure, and the mixture was stirred at room temperature for 1 hour. The precipitate was collected by filtration, washed with MeCN (10 ml), and dried under reduced pressure at 45 ° C. to convert rel- (1S, 3R, 5S) -4-aminoadamantane-1-carboxylic acid into a trans-cis cis ratio. 982 mg was obtained as a 3.5: 1 mixture.

Production Example 2
rel- (1S, 3R, 5S) -4-aminoadamantane-1-carboxylic acid (mixture with a trans to cis ratio of 3.5: 1, 100 mg) was suspended in water (4 ml) and incubated at 75 ° C for 30 minutes Stir. The mixture was returned to room temperature with stirring, and MeCN (4 ml) was slowly added dropwise, followed by stirring at the same temperature for 30 minutes. The precipitate was collected by filtration, washed with MeCN (1 ml), and dried under reduced pressure at 45 ° C. to obtain 50.0 mg of rel- (1S, 3R, 4S, 5S) -4-aminoadamantane-1-carboxylic acid.

Production Example 3
Under ice-cooling, 1M aqueous sodium hydroxide solution (0.62 ml) was added to a suspension of rel- (1S, 3R, 4S, 5S) -4-aminoadamantane-1-carboxylic acid (100 mg) in 1,4-dioxane (0.7 ml). ) And stirred for 10 minutes at the same temperature to dissolve. Under ice cooling, a solution of di-tert-butyl dicarbonate (115 mg) in 1,4-dioxane (0.1 ml) was added dropwise and stirred at room temperature for 4 hours. Under ice-cooling, 1M hydrochloric acid (0.74 ml) was added, extracted with EtOAc, washed with water (twice) and then with saturated brine. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, suspended in hexane (3 ml), collected by filtration, and 111.1 mg of rel- (1S, 3R, 4S, 5S) -4-[(tert-butoxycarbonyl) amino] adamantane-1-carboxylic acid was collected. Obtained.

Production Example 4
rel- (1S, 3R, 4S, 5S) -4-[(tert-butoxycarbonyl) amino] adamantane-1-carboxylic acid (99.0 mg) in DME (0.99 ml) suspension at room temperature with N-methylmorpholine ( 0.044 ml) was added and dissolved. Under ice cooling, isobutyl chlorocarbonate (0.052 ml) was added dropwise, and the mixture was stirred at the same temperature for 40 minutes. The precipitated white insoluble material was removed by filtration and washed with DME (0.5 ml). The filtrate was ice-cooled, sodium borohydride (25.3 mg) was added, and then MeOH (0.495 ml) was slowly added dropwise. After stirring at room temperature for 1 hour, the reaction mixture was ice-cooled and diluted with EtOAc. 1M hydrochloric acid (1.0 ml) was added to acidify, and the organic layer was separated. The organic layer was washed successively with water (twice), saturated aqueous sodium hydrogen carbonate, water and then saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was isolated and purified by silica gel column chromatography (hexane-EtOAc). The fraction containing the desired product was concentrated under reduced pressure, and the residue was dissolved in EtOAc and concentrated under reduced pressure to about 0.1 ml. Hexane (1.5 ml) is added little by little, the wall is rubbed with a spatula to crystallize, the crystals are filtered and tert-butyl rel-[(1R, 2S, 3S, 5S) -5- (hydroxymethyl) adamantane-2 77.3 mg of -yl] carbamate were obtained.

Production Example 5
Under ice cooling, TEA (600 ul) and methanesulfonyl were added to a solution of tert-butyl rel-[(1R, 2S, 3S, 5S) -5- (hydroxymethyl) adamantan-2-yl] carbamate (800 mg) in dichloromethane (16 ml). Chloride (330ul) was added and stirred at the same temperature. After 1.5 hours, water (30 ml) was added to the reaction mixture, and the mixture was extracted twice with a mixed solvent of MeOH-chloroform (1: 4) (60 ml). The organic layer was dried over anhydrous magnesium sulfate and the desiccant was removed, followed by concentration under reduced pressure. Diisopropyl ether (10 ml) was added to the obtained residue, and the mixture was concentrated again under reduced pressure, and rel-methanesulfonic acid (1S, 3R, 4S, 5S) -4-[(tert-butoxycarbonyl) amino] adamantan-1-yl} 960 mg of methyl was obtained.

Production Example 6
rel-methanesulfonic acid (1S, 3R, 4S, 5S) -4-[(tert-butoxycarbonyl) amino] adamantan-1-yl} methyl (840 mg) in DMF (8 ml) solution with sodium azide (760 mg) Water (0.6 ml) was added and stirred at 120 ° C. for 24 hours. Water (10 ml) was added to the reaction mixture and extracted with EtOAc (100 ml). The organic layer was washed twice with water (20 ml) and then with saturated brine (20 ml) and then dried over anhydrous magnesium sulfate. After removing the desiccant, it was concentrated under reduced pressure, and the residue was purified by silica gel flash column chromatography (hexane-EtOAc) to give tert-butyl rel-[(1R, 2S, 3S, 5S) -5- (azidomethyl) adamantane. 600 mg of -2-yl] carbamate were obtained.

Production Example 7
Add triphenylphosphine (300 mg) to a solution of tert-butyl rel-[(1R, 2S, 3S, 5S) -5- (azidomethyl) adamantan-2-yl] carbamate (300 mg) in THF (3 ml) at room temperature. After stirring for hours, water (1.8 ml) was added and stirred at the same temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel flash column chromatography. First elute impurities with EtOAc and elute with chloroform-MeOH-concentrated aqueous ammonia (9: 1: 0.1) to obtain tert-butyl rel-[(1R, 2S, 3S, 5S) -5- (aminomethyl) adamantane. 270 mg of -2-yl] carbamate was obtained.

Production Example 8
Under ice cooling, potassium tert-butoxide (2.40 g) was added to a DMF (36 ml) solution of di-tert-butyl iminodicarboxylate (2.79 g), and the mixture was stirred at room temperature for 1 hour. Subsequently, 3- (chloromethyl) -2- (methylsulfanyl) pyridine hydrochloride (1.80 g) was added under ice cooling, and the mixture was stirred overnight at room temperature. Water was added to the reaction mixture, and the mixture was extracted with EtOAc. The organic layer was washed with water and saturated brine, and dried over anhydrous magnesium sulfate. After removing the desiccant, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel flash column chromatography (hexane-EtOAc) to give [2- (methylsulfanyl) pyridin-3-yl] methylimide dicarbonate. 2.33 g of tert-butyl was obtained.

Production Example 9
To a solution of [2- (methylsulfanyl) pyridin-3-yl] methylimidodicarbonate di-tert-butyl (2.13 g) in 1,4-dioxane (10 ml) was added 4M hydrogen chloride dioxane solution (20 ml) at room temperature, The mixture was stirred at the same temperature for 2 hours. The solvent was distilled off under reduced pressure to obtain 1.33 g of 1- [2- (methylsulfanyl) pyridin-3-yl] methanamine dihydrochloride.

Production Example 10
Under ice cooling, a solution of 4-hydroxybicyclo [2.2.2] octane-1-carboxylic acid (100 mg) in DMF (2 ml) was charged with N, O-dimethylhydroxylamine hydrochloride (86 mg), HOBt (120 mg), 3-ethyl -1- (3-Dimethylaminopropyl) carbodiimide hydrochloride (225 mg) and DIPEA (352 ul) were sequentially added, and the mixture was stirred at room temperature for 5 hours. The reaction mixture was diluted with EtOAc (50 ml), washed twice with water (20 ml) and once with saturated brine (20 ml), and dried over anhydrous sodium sulfate. After removing the desiccant, the solvent was distilled off under reduced pressure to obtain 72 mg of 4-hydroxy-N-methoxy-N-methylbicyclo [2.2.2] octane-1-carboxamide.

Production Example 11
Under a nitrogen atmosphere at −60 ° C., a solution of 4-hydroxy-N-methoxy-N-methylbicyclo [2.2.2] octane-1-carboxamide (130 mg) in toluene (3 ml) in 1.01 M diisobutylaluminum hydride in toluene ( 1.3 ml) was added and stirred at the same temperature for 1 hour. An aqueous Rochelle salt solution (5 ml) was added to the reaction mixture, and the mixture was stirred at room temperature for 15 minutes and filtered through celite. The filtrate was concentrated under reduced pressure and purified by silica gel flash column chromatography (chloroform-MeOH) to obtain 81 mg of 4-hydroxybicyclo [2.2.2] octane-1-carbaldehyde.

Production Example 12
To a DMI solution of 4-chloro-2- (methylsulfanyl) pyrimidine-5-carbonitrile (2.2 g), DIPEA (4.13 ml), tert-butyl rel-[(1R, 2S, 3S, 5S) -5- (amino Methyl) adamantan-2-yl] carbamate (3.99 g) was added and stirred at room temperature. After completion of the reaction, the reaction mixture was diluted with EtOAc, and the organic layer was washed 3 times with water and once with saturated brine, and dried over anhydrous sodium sulfate. After removing the desiccant, the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel flash column chromatography (hexane-EtOAc) to give tert-butyl rel-[(1R, 2S, 3S, 5S) -5-({[5-cyano-2- ( Methylsulfanyl) pyrimidin-4-yl] amino} methyl) adamantan-2-yl] carbamate (4.76 g) was obtained.

Production Example 13
Tert-butyl rel-[(1R, 2S, 3S, 5S) -5-({[5-cyano-2- (methylsulfanyl) pyrimidin-4-yl] amino} methyl) adamantan-2-yl under ice-cooling ] To a solution of carbamate (4.7 g) in dichloromethane (50 ml) was added 75% MCPBA (water-containing product), and the mixture was stirred at the same temperature. After completion of the reaction, the reaction mixture was diluted with EtOAc, and the organic layer was washed once with saturated aqueous sodium bicarbonate, twice with water and once with saturated brine, and dried over anhydrous sodium sulfate. After removing the desiccant, the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel flash column chromatography (chloroform-MeOH) and tert-butyl rel-[(1R, 2S, 3S, 5S) -5-({[5-cyano-2- (methylsulfinyl ) Pyrimidin-4-yl] amino} methyl) adamantan-2-yl] carbamate (5.02 g) was obtained.

Production Example 14
Tert-butyl rel-[(1R, 2S, 3S, 5S) -5-({[5-cyano-2- (methylsulfinyl) pyrimidin-4-yl] amino} methyl) adamantan-2-yl under ice cooling ] A solution of 1- [2- (trifluoromethoxy) phenyl] methanamine (33.5 g) in DMF (100 ml) was added dropwise to a solution of carbamate (65 g) in DMF (500 ml), and the mixture was stirred at room temperature for 1 hour. Furthermore, 1- [2- (trifluoromethoxy) phenyl] methanamine (1.4 g) was added and stirred at the same temperature for 1 hour. The reaction mixture was poured into water (6000 ml) with stirring and adjusted to about pH 7.0 with 1M hydrochloric acid. The precipitated solid was collected by filtration, washed with water three times, and dried to give tert-butyl rel-[(1R, 2S, 3S, 5S) -5-{[(5-cyano-2-{[2- ( 73 g of trifluoromethoxy) benzyl] amino} pyrimidin-4-yl) amino] methyl} adamantan-2-yl] carbamate were obtained.

Production Example 20
tert-butyl rel-[(1R, 2S, 3S, 5S) -5-{[(5-cyano-2-{[2- (trifluoromethoxy) benzyl] amino} pyrimidin-4-yl) amino] methyl} TFA (60 ml) was added to a solution of adamantan-2-yl] carbamate (11.77 g) in dichloromethane (60 ml), and the mixture was stirred at room temperature for 30 minutes. After the reaction mixture was concentrated under reduced pressure, the residue was dissolved in EtOH (10 ml) and poured into 20% aqueous potassium carbonate solution (500 ml) with stirring. Potassium carbonate (50 g) was added thereto, the pH was adjusted to 11, and the precipitated solid was collected by filtration, washed 3 times with water, and then dried under reduced pressure to obtain rel-4-({[(1S, 3R, 4S, 5S 8.91 g of) -4-aminoadamantan-1-yl] methyl} amino) -2-{[2- (trifluoromethoxy) benzyl] amino} pyrimidine-5-carbonitrile was obtained.

  In the same manner as in the above production example, each production example compound was produced using the corresponding raw materials. The structures of production example compounds, production methods and physicochemical data are shown in the following table.

Example 1
rel-4-({[(1S, 3R, 4S, 5S) -4-aminoadamantan-1-yl] methyl} amino) -2-{[2- (trifluoromethoxy) benzyl] amino} pyrimidine-5- 4-Hydroxybicyclo [2.2.2] octane-1-carbaldehyde (24 mg) and sodium triacetoxyborohydride (27 mg) were added to a solution of carbonitrile (40 mg) in dichloromethane (2 ml), and the mixture was stirred at room temperature for 12 hours. . Saturated aqueous sodium hydrogen carbonate was added to the reaction mixture, and the mixture was stirred and extracted with EtOAc. The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. After removing the desiccant, the solvent was distilled off under reduced pressure, and the resulting residue was purified by amino silica gel flash column chromatography (hexane-EtOAc) to obtain rel-4-({[((1S, 3R, 4S , 5S) -4-{[(4-hydroxybicyclo [2.2.2] oct-1-yl) methyl] amino} adamantan-1-yl] methyl} amino) -2-{[2- (trifluoromethoxy) 50 mg of [benzyl] amino} pyrimidine-5-carbonitrile was obtained.

  In the same manner as in the above Examples, each Example compound was produced using the corresponding starting material. The structure, production method and physicochemical data of each Example compound are shown in the following table.

The compounds shown in the following table can be produced using the corresponding raw materials in the same manner as in the above production examples and examples.

  The compound of the formula (I) or a pharmaceutically acceptable salt thereof has a PKCθ inhibitory action and can be used as an inhibitor of acute rejection in transplantation.

Claims (10)

A compound of formula (I) or a pharmaceutically acceptable salt thereof.

(Where
R ¹ is

Indicates;
R ² represents —CN, —NO ₂ or halogen;
n represents 1 or 2;
R ³ is the same or different from each other, and is halogen, —OH, —CN, optionally substituted C _1-6 alkyl, cycloalkyl, —Q— (optionally substituted C _1-6 alkyl) or Represents -Q-cycloalkyl;
Q represents O, S, SO or SO ₂ ; and
A represents CH or N. ) R ² is —CN, —NO ₂ or —F; and
R ³ is halogen, -OH, -CN, optionally substituted with -OH C _1-6 alkyl, cycloalkyl, -Q- (halogen or C _1-6 alkyl optionally substituted with -OH ) Or -Q-cycloalkyl, or a pharmaceutically acceptable salt thereof. R ³ is halogen, -OH, -CN, optionally substituted with -OH C _1-6 alkyl, cycloalkyl, -O- (halogen or C _1-6 alkyl optionally substituted with -OH ), -S- (C _1-6 alkyl), -SO- (C _1-6 alkyl), -SO _2- (C _1-6 alkyl) or -S-cycloalkyl. Or a pharmaceutically acceptable salt thereof. R ² is -CN;
n is 1, and
R ³ is -Cl, -O-CH ₃ , -O-CHF ₂ , -O-CF ₃ , -O-CH ₂ CF ₃ or -S-CH ₃
The compound according to claim 3 or a pharmaceutically acceptable salt thereof. rel-4-({[(1S, 3R, 4S, 5S) -4-{[(4-hydroxybicyclo [2.2.2] oct-1-yl) methyl] amino} adamantan-1-yl] methyl} amino ) -2-{[2- (Trifluoromethoxy) benzyl] amino} pyrimidine-5-carbonitrile
rel-2-[(2-chlorobenzyl) amino] -4-({[(1S, 3R, 4S, 5S) -4-{[(4-hydroxybicyclo [2.2.2] oct-1-yl) methyl ] Amino} adamantan-1-yl] methyl} amino) pyrimidine-5-carbonitrile,
rel-2-{[2- (difluoromethoxy) benzyl] amino} -4-({[(1S, 3R, 4S, 5S) -4-{[(4-hydroxybicyclo [2.2.2] oct-1- Yl) methyl] amino} adamantan-1-yl] methyl} amino) pyrimidine-5-carbonitrile,
rel-4-({[(1S, 3R, 4S, 5S) -4-{[(4-hydroxybicyclo [2.2.2] oct-1-yl) methyl] amino} adamantan-1-yl] methyl} amino ) -2-{[2- (2,2,2-trifluoroethoxy) benzyl] amino} pyrimidine-5-carbonitrile,
rel-4-({[(1S, 3R, 4S, 5S) -4-{[(4-hydroxybicyclo [2.2.2] oct-1-yl) methyl] amino} adamantan-1-yl] methyl} amino ) -2-({[2- (methylsulfanyl) pyridin-3-yl] methyl} amino) pyrimidine-5-carbonitrile, and
rel-4-({[(1S, 3R, 4S, 5S) -4-{[(4-hydroxybicyclo [2.2.2] oct-1-yl) methyl] amino} adamantan-1-yl] methyl} amino ) -2-{[(2-methoxypyridin-3-yl) methyl] amino} pyrimidine-5-carbonitrile, or a pharmaceutically acceptable salt thereof, selected from the group consisting of: salt. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. The pharmaceutical composition according to claim 6, which is a PKCθ inhibitor. The pharmaceutical composition according to claim 6, which is used for suppressing acute rejection in transplantation. Use of the compound according to claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of an acute rejection inhibitor in transplantation. A method for suppressing acute rejection in transplantation, comprising administering an effective amount of the compound or salt thereof according to claim 1 to a patient.